目的 分析吉瑞替尼相关不良反应的临床特征,为临床安全合理用药提供参考。方法 检索中国知网、维普、万方、PubMed、Embase数据库关于吉瑞替尼相关不良反应的个案报道或病例分析,并进行统计分析。结果 共纳入文献13篇,共涉及患者20例,其中男性7例(35%),女性13例(65%);年龄分布以50岁以上患者居多(14例,70%);原患疾病主要为复发性或难治性急性髓系白血病(19例,95%);大部分不良反应发生在2个月以内(16例,80%);不良反应主要累及神经系统(25%),胃肠系统(17.5%)和皮肤系统(17.5%),其中严重急性肾损伤、免疫相关性肠炎和颅内出血是新发不良反应。大部分患者对症治疗后均好转,2例患者因颅内出血后出现并发症而死亡。结论 临床应加强对吉瑞替尼相关不良反应的防范,保障患者用药安全。

Objective To analyze the clinical characteristics of adverse drug reaction induced by gilteritinib, so as to provide reference for clinical safe and rational drug use. Methods Searching the case reports or studies in CNKI, VIP, Wanfang, PubMed, and Embase, the adverse drug reaction cases related to gilteritinib were statistical analyzed. Results A total of 13 literatures involving 20 patients were enrolled in our study, including 7 males (35%) and 13 females (65%). The majority of patients were over 50 years old (14 cases, 70%) and the primary disease was relapsed or refractory acute myeloid leukemia (19 cases, 95%). Most adverse drug reaction occurred within 2 months (16 cases, 80%), mainly involving nervous system (25%), gastrointestinal system (17.5%) and skin system (17.5%). Severe acute kidney injury, immune-related enteritis, and intracranial hemorrhage were the new adverse drug reaction. Most patients were improved after receiving symptomatic treatment, but 2 patients died of complications after intracranial hemorrhage. Conclusion The prevention of adverse drug reaction related to gilteritinib should be strengthened, so as to ensure the safety of patients.

R973;R979.1